Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVEONASDAQ:BCTGNASDAQ:BIVINASDAQ:CMMBNASDAQ:JAGX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsBCTGBCTG Acquisition$10.68$9.83▼$14.00$218.05MN/A36,697 shs2,024 shsBIVIBioVie$0.49-3.9%$0.74$0.45▼$8.69$20.18M0.79800,561 shs775,654 shsCMMBChemomab Therapeutics$0.66-1.5%$0.73$0.42▼$1.89$7.28M0.36190,684 shs11,539 shsJAGXJaguar Health$0.17$0.09$0.05▼$1.22$46.93M1.3586.18 million shs19.25 million shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BCTGBCTG Acquisition0.00%0.00%0.00%0.00%0.00%BIVIBioVie-3.26%+0.10%-7.95%-46.81%-93.03%CMMBChemomab Therapeutics-1.64%-5.86%-12.02%+31.80%-56.93%JAGXJaguar Health+0.06%-4.01%+146.38%+50.98%-69.09%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABCTGBCTG AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ABIVIBioVie1.822 of 5 stars3.35.00.00.02.40.00.0CMMBChemomab Therapeutics2.9409 of 5 stars3.35.00.00.02.51.70.6JAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVEOAVEO PharmaceuticalsN/AN/AN/AN/ABCTGBCTG AcquisitionN/AN/AN/AN/ABIVIBioVie2.50Moderate Buy$8.001,536.33% UpsideCMMBChemomab Therapeutics2.67Moderate Buy$7.00962.22% UpsideJAGXJaguar HealthN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVEOAVEO Pharmaceuticals$42.29M12.33N/AN/A$1.33 per share11.28BCTGBCTG AcquisitionN/AN/AN/AN/A$0.23 per shareN/ABIVIBioVieN/AN/AN/AN/A$0.42 per shareN/ACMMBChemomab TherapeuticsN/AN/AN/AN/A$1.54 per shareN/AJAGXJaguar Health$9.76M4.81N/AN/A$0.07 per share2.43Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVEOAVEO Pharmaceuticals-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/ABCTGBCTG Acquisition-$120KN/A0.00N/AN/AN/AN/AN/AN/ABIVIBioVie-$50.26M-$1.17N/A∞N/AN/A-332.18%-137.85%5/10/2024 (Estimated)CMMBChemomab Therapeutics-$24.22M-$2.12N/AN/AN/AN/A-114.00%-88.53%5/9/2024 (Confirmed)JAGXJaguar Health-$41.30MN/A0.00∞N/A-423.11%-837.11%-80.76%5/20/2024 (Estimated)Latest JAGX, CMMB, AVEO, BCTG, and BIVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024N/ACMMBChemomab Therapeutics-$0.20N/A+$0.20N/AN/AN/A4/26/2024N/ABIVIBioVieN/A-$0.33-$0.33N/AN/AN/A3/7/202412/31/2023CMMBChemomab Therapeutics-$0.40-$0.26+$0.14-$0.26N/AN/A 2/12/2024Q2 2024BIVIBioVie-$0.32-$0.22+$0.10-$0.22N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/ABCTGBCTG AcquisitionN/AN/AN/AN/AN/ABIVIBioVieN/AN/AN/AN/AN/ACMMBChemomab TherapeuticsN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVEOAVEO Pharmaceuticals0.942.372.35BCTGBCTG AcquisitionN/A4.804.80BIVIBioVieN/A1.471.47CMMBChemomab TherapeuticsN/A4.324.32JAGXJaguar Health6.332.001.34OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVEOAVEO Pharmaceuticals49.95%BCTGBCTG Acquisition62.44%BIVIBioVie4.59%CMMBChemomab Therapeutics46.05%JAGXJaguar Health12.04%Insider OwnershipCompanyInsider OwnershipAVEOAVEO Pharmaceuticals3.29%BCTGBCTG AcquisitionN/ABIVIBioVie4.80%CMMBChemomab Therapeutics11.91%JAGXJaguar Health0.16%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVEOAVEO Pharmaceuticals11434.76 million33.62 millionOptionableBCTGBCTG AcquisitionN/A21.38 millionN/ANot OptionableBIVIBioVie1839.92 million38.01 millionOptionableCMMBChemomab Therapeutics2011.05 million9.73 millionNot OptionableJAGXJaguar Health49276.22 million275.77 millionNo DataJAGX, CMMB, AVEO, BCTG, and BIVI HeadlinesSourceHeadline3 Obstacles Investors Face When Buying Penny Stockspennystocks.com - April 23 at 6:37 AMNapo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Careaccesswire.com - April 22 at 8:45 AMJaguar Health (NASDAQ:JAGX) Now Covered by StockNews.comamericanbankingnews.com - April 22 at 2:16 AMJaguar Health gets grant for treating secretory diarrhea associated with microvillous inclusion diseasepharmaceutical-technology.com - April 18 at 11:23 AMJaguar Health Appoints Biopharmaceutical Industry…pharmiweb.com - April 18 at 11:23 AMJaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Careaccesswire.com - April 18 at 8:30 AMJaguar Health licenses Venture Life's US FDA-approved oral mucositis product, Gelclair for US marketpharmabiz.com - April 18 at 6:22 AMWhy Jaguar Health Stock Is Up Todaymsn.com - April 17 at 2:20 AMGold Moves Higher; Morgan Stanley Earnings Top Viewsmarkets.businessinsider.com - April 17 at 2:20 AMWhy Is Jaguar Health (JAGX) Stock Up 44% Today?investorplace.com - April 16 at 11:34 AMJaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Careaccesswire.com - April 16 at 8:30 AMS&P 500 Down 1%; Delta Air Lines Posts Upbeat Earningsbenzinga.com - April 10 at 3:37 PMJaguar Health shareholders approve reverse stock splitmsn.com - April 10 at 3:37 PMWhat Is Going on With Jaguar Health (JAGX) Stock Today?investorplace.com - April 10 at 10:40 AMJaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholdersfinanznachrichten.de - April 10 at 1:23 AMWhy Jaguar Health Stock Is Soaring After-Hoursmsn.com - April 9 at 8:04 PMJaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholdersaccesswire.com - April 9 at 4:15 PMJaguar Health Granted Extension Until August 13, 2…pharmiweb.com - April 8 at 9:51 AMJaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirementaccesswire.com - April 8 at 8:30 AMJaguar Health Full Year 2023 Earnings: US$1.79 loss per share (vs US$36.18 loss in FY 2022)finance.yahoo.com - April 3 at 9:48 AMJaguar Health, Inc. (NASDAQ:JAGX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - April 2 at 1:47 PMJaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar Internationalaccesswire.com - April 2 at 8:50 AMJAGX Stock Earnings: Jaguar Health Misses Revenue for Q4 2023investorplace.com - April 1 at 2:08 PMJaguar Health, Inc.: Jaguar Health Reports 2023 Financial Resultsfinanznachrichten.de - April 1 at 10:51 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAVEO PharmaceuticalsNASDAQ:AVEOAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.BCTG AcquisitionNASDAQ:BCTGBCTG Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses primarily located in North America and Europe in the biotechnology industry. The company was incorporated in 2020 and is based in San Diego, California.BioVieNASDAQ:BIVIBioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Chemomab TherapeuticsNASDAQ:CMMBChemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.